Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Annelise Capossela/Axios

The goal of the COVID-19 vaccines was always to reduce death and severe illness. Even with the Delta variant, the vaccines are still doing that. But that message is getting lost, infectious disease and vaccine experts tell Axios.

The big picture: Two-thirds of the world isn't fully vaccinated. To return to some semblance of "normal," health authorities need to emphasize how the vaccines aren't failing and drastically increase global vaccine production.

Flashback: After the first vaccines were authorized and put into arms earlier this year, many people expected their high effectiveness would squash spread of the virus, especially among those who got the vaccine.

  • But the original goal, even from vaccine makers like Moderna, was to "prevent severe disease, hospitalizations and death."
  • "The idea was to take away this ability of the virus to cause severe disease," said Monica Gandhi, an infectious disease physician at the University of California San Francisco. "That's what the vaccines do. They're still doing it, even for people who received them in January, even for people who were in the vaccine trials who received them last summer."

Between the lines: Infections among the vaccinated have raised concerns, but the chances of a vaccinated person being hospitalized or dying from COVID-19 are exceptionally rare.

  • It's the unvaccinated who continue to be most at risk.
  • "People think the vaccine at some level is failing. We're doing fine," said Paul Offit, a physician and vaccine expert at Children's Hospital of Philadelphia. "The problem is, the vaccine doesn't work if you don't get it."

Zoom out: Getting more people vaccinated globally, however, means relying less on the Pfizer, Moderna and J&J shots, which are more complex to make and have not been shared equitably.

  • "The tragedy is a science policy failure," said Peter Hotez, a vaccine researcher at the Baylor College of Medicine. "Everyone was so focused on innovation that nobody took a step back and said, 'Hey, wait a minute, shouldn't we also be making vaccines that we know we can scale now?'"

What to watch: Hotez and colleagues at Texas Children's Hospital Center for Vaccine Development have created a COVID-19 vaccine called Corbevax that uses traditional vaccine technology over the newer, more expensive technology.

  • Corbevax's clinical trial results are expected to be published soon, so it's unclear exactly how effective it is.
  • But if the vaccine candidate pans out, as Hotez and others expect, it could be the cheapest, at $1.50 per dose, and easiest to produce. India is already making the vaccine at risk.
  • "Why the hell can't the Biden administration scale up and make our vaccine?" Hotez said, noting he hasn't heard much interest from federal officials. "We're getting Zoom calls a couple times a week from countries desperate for vaccine, and we're transferring the technology of our vaccine to those countries."

The bottom line: "I don't think we should move the goalpost, which is preventing serious disease and death," said Dial Hewlett, a vaccine task force expert with the National Medical Association. "The primary goal for us should be to get as many people fully vaccinated as possible."

Go deeper

19 hours ago - Health

CDC strengthens COVID booster recommendation

Rochelle Walensky. Photo: Chip Somodevilla/Getty Images

The Centers for Disease Control and Prevention (CDC) on Monday strengthened its previous recommendation for booster shots, saying that everyone 18 and older "should" receive a booster dose.

Why it matters: Last month, CDC director Rochelle Walensky accepted a key advisory committee's recommendation that adults "may" get the shot. The slight, but strengthened, change in wording comes amid the emergence of the Omicron coronavirus variant.

Federal court blocks Biden's vaccine mandate for health workers in 10 states

President Biden delivers remarks on the Omicron COVID-19 variant following a meeting with his COVID-19 response team. Photo: Anna Moneymaker via Getty Images

A federal court in Missouri has blocked the Biden administration from enforcing a coronavirus vaccine mandate for health care workers at federally funded facilities in 10 states.

Why it matters: Monday's decision is the first victory for opponents of the rule, which requires health care workers to get vaccinated by Jan. 4, 2022. The case is one of four lawsuits challenging the Centers for Medicare & Medicaid Services' (CMS) rule and argues that the mandate will exacerbate staffing shortages.

Nov 28, 2021 - Health

Moderna says updated vaccine for Omicron could be ready in early 2022

Syringes and a vial of Moderna COVID-19 vaccine. Photo: Ben Hasty/MediaNews Group/Reading Eagle via Getty Images

Moderna's chief medical officer Paul Burton said Sunday that a reformulated vaccine against the newly identified Omicron coronavirus variant could be ready as soon as early 2022 if it's found to be necessary.

Why it matters: Burton's comments on BBC's "Andrew Marr Show" come as companies are testing whether current COVID-19 vaccines will provide adequate protection against the strain.